Key result
NOACs offer simplified, cost-effective cancer-associated VTE treatment but require caution in gastrointestinal malignancies.
Why the study?
Cancer-associated venous thromboembolism is a major cause of increased morbidity and mortality, requiring appropriate risk stratification, prevention, and treatment.
Answers are grounded in this paper and cite their sources.
NOACs offer a simplified alternative to LMWH for treating cancer-associated VTE, though individualized approaches are necessary, particularly for gastrointestinal malignancies.
Cancer-associated venous thromboembolism (VTE) represents one of the major causes of increased morbidity and mortality in cancer patients. It is very important to determine the risk level in order to adequately treat the patients, but also select the patients for primary and secondary prevention of VTE and assess the risk of early death in case of acute pulmonary embolism. Nowadays the significant development in the VTE treatment in cancer patients is evident. Novel oral anticoagulants (NOACs) simplified the treatment of VTE compared to low-molecular-weight heparin (LMWH) due to their characteristics, way of administration, fixed - dose regimens and lower cost. However, their prescription requires additional caution, especially in patients with gastrointestinal malignancies. The latest available data on reperfusion therapy emphasize the importance of individual approach to each cancer patient with VTE.
No takes yet. Share an insight, caveat, or question.
Salinger et al. (2023) studied this question. Novel oral anticoagulants (NOACs) offer a simplified, cost-effective treatment for cancer-associated VTE, but require caution in patients with gastrointestinal malignancies.
Synapse has enriched 10 related papers. Consider them for comparative context: